SequelSEC

DNA X, Inc. SONM

Telephone & Telegraph Apparatus · CIK 0001178697 · Fiscal year ends 1231

Revenue
$58.30M
Fiscal year ended 2024-12-31
Operating income
-$3.10M
Fiscal year ended 2024-12-31
Free cash flow
-$8.70M
Fiscal year ended 2024-12-31

DNA X, Inc. (SONM) reported revenue of $58.30M and net income of -$33.65M for the fiscal year ended 2024-12-31. This page shows 7 annual periods of income statement, balance sheet and cash flow figures normalized from DNA X, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Telephone & Telegraph Apparatus.

Income

DNA X, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue$58.30M$93.63M$69.83M$54.57M$63.99M$116.25M$135.66M
Cost of revenue$48.38M$74.31M$58.20M$48.16M$48.78M$81.74M$87.58M
Gross profit$9.92M$19.32M$11.62M$6.41M$15.21M$34.51M$48.09M
Operating income-$3.10M$513.00K-$14.29M-$38.00M-$29.26M-$22.38M$5.39M
Net income-$33.65M-$90.00K-$14.09M-$38.63M-$29.93M-$25.83M$1.28M
Research & development$14.24M$1.77M$7.97M$17.70M$16.22M$26.06M$23.25M
Weighted-average diluted sharesUnavailableshares 4.29Mshares 28.89MUnavailableUnavailableUnavailableUnavailable
Pretax income-$2.88M$284.00K-$13.90M-$38.46M-$30.45M-$24.45M$2.03M
Income tax expense$226.00K$374.00K$184.00K$167.00K-$521.00K$1.39M$754.00K
Diluted EPS$-128.37$-0.02$-0.49UnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailable$17.04M$17.94M$19.85M$20.24M$29.00M$19.45M
General & administrative$3.10M$8.27M$10.67M$10.28M$9.83M$15.09M$7.22M
Selling & marketing$12.96M$8.77M$7.27M$9.57M$10.41M$13.91M$12.23M

Balance

DNA X, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Cash & equivalents$5.34M$9.40M$13.21M$11.23M$22.14M$11.30M$13.05M
Total assets$39.74M$56.04M$53.69M$41.09M$50.31M$55.46M$67.34M
Current assets$32.16M$43.79M$43.63M$35.69M$45.57M$47.34M$63.87M
Total liabilities$45.44M$33.68M$33.64M$22.46M$21.90M$29.93M$62.22M
Current liabilities$43.74M$32.15M$32.06M$20.98M$20.47M$27.61M$48.20M
Total equity incl. NCI-$5.70M$22.37M$20.04M$18.63M$28.41M$25.52M$5.13M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$10.62M$6.52M$3.91M$5.54M$11.34M$19.53M$21.83M
Accounts receivable$4.34M$25.30M$22.43M$10.80M$4.15M$10.08M$18.88M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable$66.00K$185.00K$362.00K$13.21M
Accounts payable$738.00K$19.85M$21.13M$9.47M$8.86M$7.23M$27.30M

Cash flow

DNA X, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Operating cash flow-$8.49M-$4.05M-$12.36M-$38.48M-$10.56M-$33.52M$3.86M
Capital expenditures$214.00K$36.00K$8.00K$46.00K$11.00K$992.00K$787.00K
Investing cash flow-$214.00K-$36.00K-$8.00K-$46.00K-$11.00K-$1.36M-$2.54M
Financing cash flow$4.65M$272.00K$14.35M$27.61M$21.41M$33.13M$10.15M
Net change in cash-$4.05M-$3.82M$1.98M-$10.91M$10.84M-$1.75M$11.47M
Stock-based compensation$1.52M$1.50M$1.55M$1.08M$1.09M$6.31M$252.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$3.56M$2.21M$2.38M$2.13M$2.73M$3.52M$1.85M

Derived

DNA X, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Free cash flow-$8.70M-$4.09M-$12.37M-$38.52M-$10.57M-$34.52M$3.07M
Gross margin17.0%20.6%16.6%11.8%23.8%29.7%35.4%
Operating marginUnavailable0.5%-20.5%-69.6%-45.7%-19.3%4.0%
FCF marginUnavailable-4.4%-17.7%-70.6%-16.5%-29.7%2.3%
SBC / revenueUnavailable1.6%2.2%2.0%1.7%5.4%0.2%
Current ratio0.74x1.36x1.36x1.70x2.23x1.71x1.33x
Revenue YoY growth-37.7%34.1%28.0%-14.7%-45.0%-14.3%Unavailable
Net marginUnavailable-0.1%-20.2%-70.8%-46.8%-22.2%0.9%
R&D / revenue24.4%1.9%11.4%32.4%25.3%22.4%17.1%
CapEx / revenueUnavailable0.0%0.0%0.1%0.0%0.9%0.6%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailable131.7%UnavailableUnavailableUnavailableUnavailable37.1%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SONM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-19View SEC filing
10-Q · Filed 2026-05-20View SEC filing
10-K · Filed 2026-04-15View SEC filing
10-Q · Filed 2025-10-31View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.